{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:53:15Z","timestamp":1790679195201,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":2611,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","award":["lyso-Gb3"],"award-info":[{"award-number":["lyso-Gb3"]}],"id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007962","name":"Jikei University School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1038\/gim.2014.28","type":"journal-article","created":{"date-parts":[[2014,3,20]],"date-time":"2014-03-20T12:22:32Z","timestamp":1395318152000},"page":"766-772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Clinical course of patients with Fabry disease who were switched from agalsidase-\u03b2 to agalsidase-\u03b1"],"prefix":"10.1016","volume":"16","author":[{"given":"Kazuya","family":"Tsuboi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/gim.2014.28_bb0010","author":"Germain"},{"key":"10.1038\/gim.2014.28_bb0015","author":"Mehta"},{"key":"10.1038\/gim.2014.28_bb0020","author":"Ramaswami"},{"key":"10.1038\/gim.2014.28_bb0025","author":"Mehta"},{"key":"10.1038\/gim.2014.28_bb0030","author":"Lidove"},{"key":"10.1038\/gim.2014.28_bb0035","author":"Keating"},{"key":"10.1038\/gim.2014.28_bb0040","author":"West"},{"key":"10.1038\/gim.2014.28_bb0045","author":"Lee"},{"key":"10.1038\/gim.2014.28_bb0050","author":"Sakuraba"},{"key":"10.1038\/gim.2014.28_bb0055","author":"Huby"},{"key":"10.1038\/gim.2014.28_bb0060","series-title":"Fabry Disease: Perspectives from 5 Years of FOS.","article-title":"Importance of glycosylation in enzyme replacement therapy","author":"Bekri","year":"2006"},{"key":"10.1038\/gim.2014.28_bb0065","unstructured":"European Medicines Agency. Assessment report on the shortage of Fabrazyme. Overview of shortage period: spontaneous reports from June 2009 through 15 September 2010 and registry data from June 2009 through 05 August 2010. EMEA\/H\/C\/000370. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Other\/2010\/11\/WC500099241.pdf Accessed December 2012."},{"key":"10.1038\/gim.2014.28_bb0070","unstructured":"European Medicines Agency. European Medicines Agency reviews treatment recommendations for Fabrazyme. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2010\/10\/WC500098370.pdf Accessed December 2012."},{"key":"10.1038\/gim.2014.28_bb0075","author":"European Medicines Agency"},{"key":"10.1038\/gim.2014.28_bb0080","author":"Tsuboi"},{"key":"10.1038\/gim.2014.28_bb0085","author":"CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)"},{"key":"10.1038\/gim.2014.28_bb0090","author":"Devereux"},{"key":"10.1038\/gim.2014.28_bb0095","author":"Chamber Quantification Writing Group; American Society of Echocardiography\u2019s Guidelines and Standards Committee; European Association of Echocardiography"},{"key":"10.1038\/gim.2014.28_bb0100","author":"Tan"},{"key":"10.1038\/gim.2014.28_bb0105","author":"The EuroQoL Group."},{"key":"10.1038\/gim.2014.28_bb0110","author":"Whybra"},{"key":"10.1038\/gim.2014.28_bb0115","author":"Linthorst"},{"key":"10.1038\/gim.2014.28_bb0120","author":"Smid"},{"key":"10.1038\/gim.2014.28_bb0125","author":"Pisani"},{"key":"10.1038\/gim.2014.28_bb0130","author":"van Breemen"},{"key":"10.1038\/gim.2014.28_bb0135","author":"Maisel"},{"key":"10.1038\/gim.2014.28_bb0140","author":"Yasuda"},{"key":"10.1038\/gim.2014.28_bb0145","author":"Linthorst"},{"issue":"suppl 3","key":"10.1038\/gim.2014.28_bb0150","first-page":"S245","article-title":"Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha","volume":"33","author":"Tanaka","year":"2010","journal-title":"J Inherit Metab Dis"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/gim201428.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/gim201428","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360021031737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360021031737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/gim201428.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:44:33Z","timestamp":1761097473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360021031737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1098360021031737"],"URL":"https:\/\/doi.org\/10.1038\/gim.2014.28","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical course of patients with Fabry disease who were switched from agalsidase-\u03b2 to agalsidase-\u03b1","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/gim.2014.28","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014, The Author(s), under exclusive licence to the American College of Medical Genetics and Genomics","name":"copyright","label":"Copyright"}]}}